HOME >> MEDICINE >> NEWS
Common Drug-Capsule Coating Not As Inert As Previously Thought

CHAMPAIGN, Ill. -- Polyethylene glycol (PEG) is widely used for drug encapsulation and as a protective surface coating for biomedical applications. Its popularity as a surface coating has been based -- in part -- on the belief that the material forms an inert, steric barrier that prevents proteins and other biological materials from sticking to foreign or man-made materials. Recent work at the University of Illinois, however, has revealed that this polymer is not as inert as researchers thought.

Chemical engineering professor Deborah Leckband and graduate student Shailesh Sheth used a surface-force apparatus to measure the molecular forces between two membranes supporting PEG and the protein streptavidin. The researchers discovered that PEG can undergo attractive interactions with the proteins that will result in the latter binding to the polymer surface.

"Not only did the polymer switch from a protein-resistant state to a protein-attractive state, we found the presence of the protein appeared to induce a change in the polymer configuration," Leckband said. "This suggests there may be some additional structure in the polymer backbone that is important in maintaining the inert or protein-evasive property."

Leckband and Sheth's research indicates that PEG may work well for short periods -- to extend drug delivery times in the bloodstream, for example -- but over longer periods, the polymer's structure may change, making it less repulsive and potentially more biologically active.

"This is particularly important in applications such as implants and artificial scaffolds, where polymer-coated materials are in contact with living tissue for extremely long periods of time," Leckband said. "Implicit in such long-term applications is the requirement that the polymer does not perturb the various protein structures and trigger an unwanted biological response that would lead to rejection."

One of the current problems in the desig
'"/>

Contact: James Kloeppel, Physical Sciences Editor
kloeppel@uiuc.edu
217-244-1073
University of Illinois at Urbana-Champaign
3-Oct-1997


Page: 1 2

Related medicine news :

1. Common anesthetics appear safe for developing fetal brain
2. Common schizophrenia symptoms often overlooked by physicians, according to expert panel
3. Common antidepressants lower effects of tamoxifen in many women
4. Common antidepressant may affect youths bone development
5. Common epilepsy treatment to be used for bulimia nervosa
6. Mouth sores: Common complaints of students
7. Common drug, given promptly, reduces incidence of post-traumatic stress disorder, small study finds
8. New Commonwealth Fund analysis compares candidtes health care reform proposals
9. Common heart surgery potentially dangerous
10. Common treatment for cancer pain stimulates breast tumor growth in mice
11. Common diabetes drug causes arteries to spasm, endangering heart

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Common Drug Capsule Coating Not Inert Previously Thought

(Date:6/19/2013)... (PRWEB) June 19, 2013 Kansas City will host ... Main Street Day . A section of Main Street in ... during the afternoon of the event. The Main Street Corridor ... event, which will help Kansas City join the ranks of dozens ... as a tool to foster community vibrancy and active lifestyles. , ...
(Date:6/19/2013)... In 2011, the value of the ... Generic drugs form the largest sector, accounting for nearly ... industry is a significant contributor to the local economy; ... Approximately 50% of the total domestic chemical industry output ... Galenika and Zdravlje Actavis are key participants in the ...
(Date:6/19/2013)... 19, 2013 Elsevier, a world-leading provider of ... announced today the publication of the National Osteoporosis ... management of osteoporosis in postmenopausal women and older ... Published in 2009 in Maturitas , the ... update is timely with an additional focus on ...
(Date:6/19/2013)... Next Thursday, June 27, 2013, ... organization, and Muzzy Lane Software , a ... the Games for Health community to their interactive ... toward students in grades 4-7 and designed to ... positive choices. The game is part of a ...
(Date:6/19/2013)... Maui'd Forever , Hawaii's premiere ... an effective and cost effective way to provide for ... up with Tom Barefoot’s Tours providing an activity agent ... Hawaii’s activities. , They have just released a new ... lowest prices on their Hawaii activities. , Maui’d ...
Breaking Medicine News(10 mins):Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3Health News:Serbian Pharmaceutical Market Scrutinized by CUBE in Topical Report Now Available at MarketPublishers.com 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 4Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 5Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2
(Date:6/19/2013)... NESS ZIONA, Israel , ... today announced that results from a phase I study ... study in advanced Parkinson,s patients, of ND0612, were presented ... Movement Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug ... (SC) delivery patch that would maintain constant levodopa plasma ...
(Date:6/19/2013)... 19, 2013  This year alone, The Leukemia & ... projects with one goal in mind: Discovering lifesaving therapies ... Training" (TNT), a flagship LLS fundraising campaign and the ... marking its landmark 25 th anniversary. To date, ... in research to discover and deliver breakthrough cancer treatments ...
(Date:6/19/2013)... June 19, 2013   Life Technologies Corporation ... licensing agreement granting Suzhou Ribo Life Sciences (Ribo) ... therapeutics in China using ... proprietary siRNA molecules in combination with Invivofectamine® Rx ... human diseases with high unmet medical need in ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4
Cached News: